[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631231":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":21,"slug":7,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":26,"phases":7,"briefSummary":27,"conditions":28,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":35,"locationsCount":7},{"fullName":5,"class":6},"ITM Solucin GmbH","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","ITM-11","Intravenous (IV) infusion",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Medical Affairs","CONTACT","609-785-5839","medical.affairs@itm-radiopharma.com",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100631231",false,"NCT07497984","ITM11 Expanded Access Program","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","This Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´s medical history and the program eligibility criteria, whether the potential benefits outweigh the risks of treatment with an investigational therapy.",[29],"Meningioma","AVAILABLE","2026-03-23",{"date":33,"type":34},"2026-03-27","ACTUAL",{"name":5,"class":6}]